Science

Dec 29, 2024, 10:10

Neoadjuvant atezolizumab plus chemotherapy for resectable NSCLC

Journal for ImmunoTherapy of Cancer posted on X about recent paper by Brian S. Henick et al., titled “Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings“.

Authors: Brian S. Henick, Peter D. Koch, Justin F. Gainor, Mark M. Awad, Codruta Chiuzan, Stephanie Izard, Yohanna Georgis, Samyukta Mallick, Robert F. Garofano, Cheryl V. Wong, Anjali Saqi, Jessica Grindheim, Katja Schulze, Joshua R. Sonett, Naiyer A. Rizvi, Benjamin Izar, Alison M. Taylor, Catherine A. Shu

“New JITC article: Neoadjuvant atezolizumab + chemotherapy for resectable NSCLC: 3-year clinical update of phase II clinical trial results and translational findings.”

Alison M. Taylor Anjali Saqi Benjamin Izar Brian S Henick cancer Catherine A. Shu Cheryl V. Wong Codruta Chiuzan Jessica Grindheim Joshua R. Sonett Journal for ImmunoTherapy of Cancer Justin F. Gainor Katja Schulze Mark M. Awad Naiyer A. Rizvi NSCLC OncoDaily Oncology Peter D. Koch Robert F. Garofano Samyukta Mallick Stephanie Izard Yohanna Georgis

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25

Egypt Cancer Society (ECS) and OncoDaily Announce Strategic Partnership to Advance Global Cancer Care